On the stock market since 2013, it operates in the world of health and science. It has 114 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 85% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
The company sells $225.9M a year; the problem isn’t sales — it’s costs running above that number.
There is $591.3M in the vault; even if every debt were paid off, $581.6M would remain.
A loss of $332.0M against $225.9M in annual sales.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, BOVNF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BOVNF is a small company that closed last year at a loss. The road back to profit runs through spending discipline.